{"disease":{"id":"glucose-transporter-type-1-deficiency-syndrome","name":"glucose transporter type 1 deficiency syndrome"},"drugs":{"marketed":[],"pipeline":[],"offLabel":[],"totalMarketed":0,"totalPipeline":0},"trials":{"data":[{"nct_id":"NCT03655223","title":"Early Check: Expanded Screening in Newborns","phase":"","overall_status":"ENROLLING_BY_INVITATION","enrollment_count":30000,"lead_sponsor_name":"RTI International","has_results":false},{"nct_id":"NCT03181399","title":"Diet Treatment Glucose Transporter Type 1 Deficiency (G1D)","phase":"PHASE2","overall_status":"COMPLETED","enrollment_count":45,"lead_sponsor_name":"University of Texas Southwestern Medical Center","has_results":true},{"nct_id":"NCT02960217","title":"Crossover Study to Assess the Efficacy and Safety of UX007 in the Treatment of Movement Disorders Associated With Glucose Transporter Type 1 Deficiency Syndrome (Glut1 DS)","phase":"PHASE3","overall_status":"TERMINATED","enrollment_count":44,"lead_sponsor_name":"Ultragenyx Pharmaceutical Inc","has_results":true},{"nct_id":"NCT01993186","title":"Phase 2 Study of Triheptanoin (UX007) for the Treatment of Glucose Transporter Type 1 Deficiency Syndrome (Glut1 DS)","phase":"PHASE2","overall_status":"COMPLETED","enrollment_count":36,"lead_sponsor_name":"Ultragenyx Pharmaceutical Inc","has_results":true},{"nct_id":"NCT04399954","title":"Evaluation of Ketoflo","phase":"NA","overall_status":"COMPLETED","enrollment_count":25,"lead_sponsor_name":"Vitaflo International, Ltd","has_results":false},{"nct_id":"NCT05085704","title":"Brain Metabolism Observed at 7 Tesla","phase":"","overall_status":"RECRUITING","enrollment_count":20,"lead_sponsor_name":"University of Texas Southwestern Medical Center","has_results":false},{"nct_id":"NCT02036853","title":"An Open-Label Trial of Triheptanoin in Patients With Glucose Transporter Type-1 Deficiency Syndrome","phase":"PHASE2","overall_status":"COMPLETED","enrollment_count":20,"lead_sponsor_name":"Adrian Lacy","has_results":true},{"nct_id":"NCT02599961","title":"Study to Assess the Long Term Safety and Efficacy of UX007 in Participants With Glucose Type 1 Deficiency Syndrome (Glut1 DS)","phase":"PHASE2","overall_status":"TERMINATED","enrollment_count":15,"lead_sponsor_name":"Ultragenyx Pharmaceutical Inc","has_results":true},{"nct_id":"NCT03041363","title":"Treatment Development of Triheptanoin (G1D)","phase":"PHASE1","overall_status":"COMPLETED","enrollment_count":12,"lead_sponsor_name":"Juan Pascual","has_results":false},{"nct_id":"NCT03202108","title":"Evaluation of Krio in Children and Adults With Epilepsy","phase":"NA","overall_status":"WITHDRAWN","enrollment_count":0,"lead_sponsor_name":"Vitaflo International, Ltd","has_results":false},{"nct_id":"NCT02018302","title":"Post Study Continuation of C7 for G1D","phase":"","overall_status":"NO_LONGER_AVAILABLE","enrollment_count":null,"lead_sponsor_name":"Juan Pascual","has_results":false}],"total":11},"guidelines":[],"source":"Drug Landscape verified database"}